drug

Enstilar

Marketedupdated 2mo ago

by Perrigo New York Inc

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

Patent cliff

source: FDA Orange Book

first barrier falls

Sep 27, 2027

~1.2 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (13)

Mar 18, 2039formulationUS 11696919
Mar 18, 2039formulationUS 12440499
Dec 10, 2031patentUS 10130640*PED
Dec 10, 2031patentUS 9119781*PED
Jun 10, 2031formulationUS 101306404.9y
Jun 10, 2031formulationUS 106176984.9y
Jun 10, 2031formulationUS 106609084.9y
Jun 10, 2031formulationUS 106823644.9y
Jun 10, 2031method-of-use (U-2627)US 106881084.9y
Jun 10, 2031formulationUS 107167994.9y
Jun 10, 2031formulationUS 91197814.9y
Jun 10, 2031formulationUS 95662864.9y
Sep 27, 2027formulationUS 102652651.2y

Data sources

ClinicalTrials.gov

last refreshed 47m ago

Found something off?

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Trials studying Enstilar

phase4A Study Evaluating the Efficacy and Tolerability of Enstilar Foam in Patients With Nail Psoriasiscompletedn=6